What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the anti-asthmatic agent Tranilast into an anti-HIV agent: Tranilast (trade name: Rizaben and others) increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 26/February/2020, 11.07 pm
From Significance of the study to Public health relevance:
Given that: (1) more than 37 million people worldwide are living with HIV/AIDS; (2) there is no effective vaccine available for HIV/AIDS; (3) HIV/AIDS tops the list of incurable diseases in humans; (4) the life-long painful drug treatment is required to treat HIV/AIDS and its associated opportunistic infections; (5) the global economic cost spent for HIV treatment is enormous, there is an urgent need to find: (i) a way to restore CD4 T-cells that were lost in HIV/AIDS; (ii) a cheaper alternative to the existing expensive antiviral drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, HIV-1/AIDS.
Research findings to Therapeutic opportunity:
This study suggests, for the first time, an anti-hypertensive drug-based antiviral therapy against RNA viruses, such as HIV-1. Tranilast (trade name: Rizaben & others), by increasing the expression of its target gene, it may increase the expression of Heme oxygenase-2 (HO-2) (Figure 1). Thereby, it may: (1) bind and block the myristate moiety of HIV-1 Gag protein; (2) disrupt HIV-1 budding; (3) restrict HIV-1 infectivity, replication, and production; (4) promote clearance of HIV-1 and MLV virions; and (5) strengthen antiviral immunity against RNA viruses (fig.2).
Thus, pharmacological formulations encompassing “Tranilast or its analogs, either alone or in combination with other drugs,” may be used to inhibit HIV-1 production. Together, this study suggests that (1) Tranilast may function as an anti-retroviral agent against HIV infections; and (2) daily intake of Tranilast (low dose) may protect against HIV1 infections.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Tranilast increase the expression of Heme oxygenase-2 (HO-2)?
For payment and purchase details, you may reach us at email@example.com
# Research cooperation
Citation: Boominathan, L., Repurposing the anti-asthmatic agent Tranilast into an anti-HIV agent: Tranilast (trade name: Rizaben and others) increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 26/February/2020, 11.07 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at firstname.lastname@example.org